CLINICAL_TRIALS
trial_result
· 2018-11-13
Clinical Trial Update: Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure [Phase 3]
Summary
Phase 3 trial evaluating a dolutegravir-based antiretroviral strategy to improve outcomes and reduce drug exposure in HIV infection.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Babafemi Taiwo | Conditions: HIV Infection | Phase 3 | Status: COMPLETED | Results posted: 2018-11-13